Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer

European Urology

Volumn 71, Issue 6, 2017, Pages 961-969

  Christensen, Emil ^a   Birkenkamp Demtröder, Karin ^a   Nordentoft, Iver ^a   Høyer, Søren ^a   van der Keur, Kirstin ^b   van Kessel, Kim ^b   Zwarthoff, Ellen ^b   Agerbæk, Mads ^a   Ørntoft, Torben Falck ^a   Jensen, Jørgen Bjerggaard ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Biomarker; Cell free DNA; Droplet digital polymerase chain reaction; FGFR3; Liquid biopsy; Personalised analysis; PIK3CA

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; CIRCULATING TUMOR DNA; FGFR3 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SURVEILLANCE; DNA SCREENING; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIQUID BIOPSY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; URINALYSIS; URINE SAMPLING; BLADDER TUMOR; BLOOD; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MUTATION; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; URINE;

AGED; BIOMARKERS, TUMOR; CIRCULATING TUMOR DNA; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LIQUID BIOPSY; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85008699089     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.12.016     Document Type: Article

References (30)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. [2] Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–61.
3. [3] Kirkali, Z., Chan, T., Manoharan, M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005), 4–34.
4. [4] Stein, J.P., Skinner, D.G., Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 24 (2006), 296–304.
5. [5] Stein, J.P., Lieskovsky, G., Cote, R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001), 666–675.
6. [6] von der Maase, H., Sengelov, L., Roberts, J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005), 4602–4608.
7. [7] Svatek, R.S., Hollenbeck, B.K., Holmang, S., et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66 (2014), 253–262.
8. [8] Groenendijk, F.H., de Jong, J., Fransen van de Putte, E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69 (2016), 384–388.
9. [9] Hedegaard, J., Lamy, P., Nordentoft, I., et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30 (2016), 27–42.
10. [10] Sjodahl, G., Lauss, M., Lovgren, K., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18 (2012), 3377–3386.
11. [11] Allory, Y., Beukers, W., Sagrera, A., et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65 (2014), 360–366.
12. [12] Kompier, L.C., Lurkin, I., van der Aa, M.N., van Rhijn, B.W., van der Kwast, T.H., Zwarthoff, E.C., FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One, 5, 2010, e13821.
13. [13] Reinert, T., Modin, C., Castano, F.M., et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 17 (2011), 5582–5592.
14. [14] Zuiverloon, T.C., Tjin, S.S., Busstra, M., Bangma, C.H., Boeve, E.R., Zwarthoff, E.C., Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. J Urol 186 (2011), 707–712.
15. [15] Heitzer, E., Ulz, P., Geigl, J.B., Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61 (2015), 112–123.
16. [16] Botezatu, I., Serdyuk, O., Potapova, G., et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 46 (2000), 1078–1084.
17. [17] Birkenkamp-Demtroder, K., Nordentoft, I., Christensen, E., et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70 (2016), 75–82.
18. [18] Garcia-Murillas, I., Schiavon, G., Weigelt, B., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med, 7, 2015, 302ra133.
19. [19] Reinert, T., Scholer, L.V., Thomsen, R., et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65 (2016), 625–634.
20. [20] Jensen, J.B., Munksgaard, P.P., Sorensen, C.M., et al. High expression of karyopherin-alpha2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy. Eur Urol 59 (2011), 841–848.
21. [21] Schepeler, T., Lamy, P., Hvidberg, V., et al. A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response. Oncogene 32 (2013), 3577–3586.
22. [22] Jamal-Hanjani, M., Wilson, G.A., Horswell, S., et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol 27 (2016), 862–867.
23. [23] Salvi, S., Martignano, F., Molinari, C., et al. The potential use of urine cell free DNA as a marker for cancer. Expert Rev Mol Diagn 16 (2016), 1283–1290.
24. [24] Murtaza, M., Dawson, S.J., Pogrebniak, K., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun, 6, 2015, 8760.
25. [25] Siravegna, G., Mussolin, B., Buscarino, M., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med, 21, 2015, 827.
26. [26] van Rhijn, B.W., Vis, A.N., van der Kwast, T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003), 1912–1921.
27. [27] Platt, F.M., Hurst, C.D., Taylor, C.F., Gregory, W.M., Harnden, P., Knowles, M.A., Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15 (2009), 6008–6017.
28. [28] Critelli, R., Fasanelli, F., Oderda, M., et al. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget 7:41 (2016), 67435–67448, 10.18632/oncotarget.11883.
29. [29] Kompier, L.C., van der Aa, M.N., Lurkin, I., et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol 218 (2009), 104–112.
30. [30] Thomsen, M.B., Nordentoft, I., Lamy, P., et al. Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Mol Oncol 10 (2016), 1450–1460.